Liping Dou: Clinical Trials

13 trials sponsored by Liping Dou, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 recruiting, 3 not yet recruiting, 2 active not recruiting. 8 Phase 1, 7 Phase 2, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 18Recruiting 4, Not yet recruiting 3, Active not recruiting 1
Phase 27Recruiting 5, Active not recruiting 2
Early Phase 11Recruiting 1

Follow Liping Dou: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
CLL-1-CD70 CAR-T Cell Injection - Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia
Phase 1Not yet recruitingLiping Dou122026-11-302026-10-27
BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma
SL4903 Injection (BCMA/GPRC5D Dual-Target Autologous CAR-T Cell Injection) - Multiple Myeloma; Relapsed/Refractory Multiple Myeloma
Phase 1Not yet recruitingLiping Dou202026-11-302026-11-10
CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia
SL1CC Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)
Phase 1Not yet recruitingLiping Dou122026-10-012026-10-02
CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
CD19-Targeted In Vivo CAR-T Injection (first infusion, Day 0); CD22 -Targeted In Vivo CAR-T Injection (second infusion, Day 7) - Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, In Vivo CAR-T
Phase 1RecruitingLiping Dou122026-09-012026-11-10
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
BCL-2 inhibitor, Zemestosita, Azacitidine, Cytarabine, Chidamide, and G-CSF - R/R AML
Phase 2Active not recruitingLiping Dou322026-07-302026-10-15
Romiplostim for Platelet Engraftment After Haploidentical or Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation
Romiplostim, Best Supportive Care (BSC) - Hematologic Diseases
Phase 2RecruitingLiping Dou1202026-06-012026-11-06
In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms
In vivo BCMA/GPRC5D Tandem Dual CAR-T cell - Plasma Cell Neoplasms
Early Phase 1RecruitingLiping Dou182026-05-092026-10-02
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
CD22/CD19 CAR-T cell immunotherapy - Lymphoma
Phase 2RecruitingLiping Dou302026-04-012026-08-21
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2RecruitingLiping Dou202026-01-012026-06-15
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
CD22/CD19 CAR-T cell immunotherapy - Lymphoma
Phase 2RecruitingLiping Dou202026-01-012026-05-14
Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
CD22/CD19 Dual-Target CAR-T Cells - B-cell Acute Lymphoblastic Leukemia
Phase 1 / Phase 2RecruitingLiping Dou302026-01-012026-06-25
A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT
Azacitidine (AZA) Days 1 - 5, Selinexor - Acute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)
Phase 1 / Phase 2Active not recruitingLiping Dou582025-05-012026-08-21
Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
Blinatumomab Injection, Donor Lymphocyte Infusion (DLI) - ALL (Acute B-Lymphoblastic Leukemia)
Phase 1RecruitingLiping Dou602024-12-012026-07-01

Conditions studied

Burkitt Lymphoma (3)  ·  Leukemia, Myeloid, Acute (3)  ·  Recurrence (3)  ·  Cytokine Release Syndrome (2)  ·  Lymphoma (2)  ·  Neoplasm, Residual (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Hematologic Diseases (1)  ·  Multiple Myeloma (1)  ·  Neoplasms, Plasma Cell (1)

Interventions

Azacitidine (2)  ·  Cytarabine (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1)  ·  blinatumomab (1)  ·  romiplostim (1)  ·  selinexor (1)

Countries

China (13)

Top investigators

Li-Ping Dou, Dr. (1)